BOSTON, Nov. 02, 2022 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. SNSEan immuno-oncology company focused on the discovery and development of next-generation cancer therapeutics, today announced that John Celebi, President and Chief Executive Officer, will speak at the 13th Annual Jefferies Global Healthcare Conference in London, UK will hold. on Thursday 17 November 2022 at 7:25 GMT.
A webcast of Sensei’s presentation will be available in investors section of the Sensei website. A replay of the webcast will be available on the website approximately 90 days after the event. Registration for the live webcast is available here.
About Sensei biotherapeutics
Sensei biotherapeutics SNSE is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated Biologicals) platform, Sensei is developing conditionally active therapeutics designed to selectively disable checkpoints and other immunosuppressive signals in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to selectively block the V domain Ig suppressor of T cell activation (VISTA) checkpoint within the low pH tumor microenvironment , where VISTA acts as a suppressor of T cells by targeting the PSGL-1 receptor. For more information, please visit www.senseibio.comand follow the company…
